Preventing Breast Cancer in High-Risk Women: Is There Still a Role for Oophorectomy?

por Norquist, Barbara M, Swisher, Elizabeth M, Yung, Rachel L
Publicado 2019

Premalignant alterations in breast and endometrium associated with a PTEN mutation in a woman with Cowden syndrome: implications for preventive care()

por Morse, Christopher B., Garcia, Rochelle L., Calhoun, Kristine E., Swisher, Elizabeth M.
Publicado 2015

PARP Inhibitors and Myeloid Neoplasms: A Double-Edged Sword

por Csizmar, Clifford M., Saliba, Antoine N., Swisher, Elizabeth M., Kaufmann, Scott H.
Publicado 2021

Barriers, interventions, and recommendations: Improving the genetic testing landscape

por Dusic, E. J., Theoryn, Tesla, Wang, Catharine, Swisher, Elizabeth M., Bowen, Deborah J.
Publicado 2022

Sertoli-Leydig cell tumor associated with a germline DICER1 pathogenic variant diagnosed during pregnancy: Considerations for treatment, surveillance, and prevention

por Wang, Joyce Y., Ma, Kimberly K., Reiter, Daniel J., Torvie, Ana, Swisher, Elizabeth M.
Publicado 2023

Real‐World Delivery of Rucaparib to Patients with Ovarian Cancer: Recommendations Based on an Integrated Safety Analysis of ARIEL2 and Study 10

por Drew, Yvette, Kristeleit, Rebecca S., Oaknin, Ana, Ray‐Coquard, Isabelle, Haris, Noor Md., Swisher, Elizabeth M.
Publicado 2019

Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas

por Swisher, Elizabeth M, Gonzalez, Rachel M, Taniguchi, Toshiyasu, Garcia, Rochelle L, Walsh, Tom, Goff, Barbara A, Welcsh, Piri
Publicado 2009

Reflex test reminders in required cancer synoptic templates decrease order entry error: An analysis of mismatch repair immunohistochemical orders to screen for Lynch syndrome

por Kilgore, Mark R., McIlwain, Carrie A., Schmidt, Rodney A., Norquist, Barbara M., Swisher, Elizabeth M., Garcia, Rochelle L., Rendi, Mara H.
Publicado 2016

Patterns and duration of primary and recurrent treatment in ovarian cancer patients with germline BRCA mutations

por Jorge, Soledad, Swisher, Elizabeth M., Norquist, Barbara M., Pennington, Kathryn P., Gray, Heidi J., Urban, Renata R., Garcia, Rochelle L., Doll, Kemi M.
Publicado 2019

Mathematical modeling of the early modeled CA-125 longitudinal kinetics (KELIM-PARP) as a pragmatic indicator of rucaparib efficacy in patients with recurrent ovarian carcinoma in...

por Colomban, Olivier, Swisher, Elizabeth M., Kristeleit, Rebecca, McNeish, Iain, Shapira-Frommer, Ronnie, Goble, Sandra, Lin, Kevin K., Maloney, Lara, Freyer, Gilles, You, Benoit
Publicado 2023

Long-term survival of an ovarian cancer patient harboring a RAD51C missense mutation

por Sullivan, Meghan R., Prakash, Rohit, Rawal, Yashpal, Wang, Weibin, Sung, Patrick, Radke, Marc R., Kaufmann, Scott H., Swisher, Elizabeth M., Bernstein, Kara A., Jasin, Maria
Publicado 2021

Safety and pharmacokinetics of veliparib extended‐release in patients with advanced solid tumors: a phase I study

por Werner, Theresa L., Sachdev, Jasgit, Swisher, Elizabeth M., Gutierrez, Martin, Kittaneh, Muaiad, Stein, Mark N., Xiong, Hao, Dunbar, Martin, Sullivan, Danielle, Komarnitsky, Philip, McKee, Mark, Tan, Antoinette R.
Publicado 2018

Genomic and epigenomic BRCA alterations predict adaptive resistance and response to platinum-based therapy in patients with triple negative breast and ovarian carcinomas

por Menghi, Francesca, Banda, Kalyan, Kumar, Pooja, Straub, Robert, Dobrolecki, Lacey, Rodriguez, Isabel V., Yost, Susan E., Chandok, Harshpreet, Radke, Marc R., Somlo, George, Yuan, Yuan, Lewis, Michael T., Swisher, Elizabeth M., Liu, Edison T.
Publicado 2022

BRCA1 intronic Alu elements drive gene rearrangements and PARP inhibitor resistance

por Wang, Yifan, Bernhardy, Andrea J., Nacson, Joseph, Krais, John J., Tan, Yin-Fei, Nicolas, Emmanuelle, Radke, Marc R., Handorf, Elizabeth, Llop-Guevara, Alba, Balmaña, Judith, Swisher, Elizabeth M., Serra, Violeta, Peri, Suraj, Johnson, Neil
Publicado 2019

MAGENTA (Making Genetic testing accessible): a prospective randomized controlled trial comparing online genetic education and telephone genetic counseling for hereditary cancer gen...

por Rayes, Nadine, Bowen, Deborah J., Coffin, Tara, Nebgen, Denise, Peterson, Christine, Munsell, Mark F., Gavin, Kathleen, Lechner, Rebecca, Crase, Jamie, Polinsky, Deborah, Romero, Iris, Blank, Stephanie V., Levine, Douglas A., Norquist, Barbara M., Swisher, Elizabeth M., Lu, Karen H.
Publicado 2019

TUBectomy with delayed oophorectomy as an alternative to risk-reducing salpingo-oophorectomy in high-risk women to assess the safety of prevention: the TUBA-WISP II study protocol

por Steenbeek, Miranda P, van Bommel, Majke H D, intHout, Joanna, Peterson, Christine B, Simons, Michiel, Roes, Kit C B, Kets, Marleen, Norquist, Barbara M, Swisher, Elizabeth M, Hermens, Rosella P M G, Lu, Karen H, de Hullu, Joanne A
Publicado 2023

An integrative genomic approach identifies p73 and p63 as activators of miR-200 microRNA family transcription

por Knouf, Emily C., Garg, Kavita, Arroyo, Jason D., Correa, Yesenia, Sarkar, Deepayan, Parkin, Rachael K., Wurz, Kaitlyn, O’Briant, Kathy C., Godwin, Andrew K., Urban, Nicole D., Ruzzo, Walter L., Gentleman, Robert, Drescher, Charles W., Swisher, Elizabeth M., Tewari, Muneesh
Publicado 2012

CA-125 KELIM as a Potential Complementary Tool for Predicting Veliparib Benefit: An Exploratory Analysis From the VELIA/GOG-3005 Study

por You, Benoit, Sehgal, Vasudha, Hosmane, Balakrishna, Huang, Xin, Ansell, Peter J., Dinh, Minh H., Bell-McGuinn, Katherine, Luo, Xizhi, Fleming, Gini F., Friedlander, Michael, Bookman, Michael A., Moore, Kathleen N., Steffensen, Karina D., Coleman, Robert L., Swisher, Elizabeth M.
Publicado 2023

Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer

por Lee, Jung-Min, Hays, John L., Chiou, Victoria L., Annunziata, Christina M., Swisher, Elizabeth M., Harrell, Maria I., Yu, Minshu, Gordon, Nicolas, Sissung, Tristan M., Ji, Jiuping, Figg, William D., Minasian, Lori, Lipkowitz, Stanley, Wood, Bradford J., Doroshow, James, Kohn, Elise C.
Publicado 2017

Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first in class, proof-of-concept, single arm phase 2...

por Lee, Jung-Min, Nair, Jayakumar, Zimmer, Alexandra, Lipkowitz, Stanley, Annunziata, Christina M., Merino, Maria J., Swisher, Elizabeth M., Harrell, Maria I., Trepel, Jane B., Lee, Min-Jung, Bagheri, Mohammad H., Botesteanu, Dana-Adriana, Steinberg, Seth M., Minasian, Lori, Ekwede, Irene, Kohn, Elise C.
Publicado 2018